NASDAQ:CFRX ContraFect - CFRX Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding ContraFect Co. Please log in to your account or sign up in order to add this asset to your watchlist. $0.09 -0.01 (-8.49%) (As of 01/26/2023 04:01 PM ET) Add Compare Share Share Today's Range$0.09▼$0.1050-Day Range$0.09▼$0.1852-Week Range$0.08▼$4.54Volume19.78 million shsAverage Volume19.90 million shsMarket Capitalization$4.00 millionP/E RatioN/ADividend YieldN/APrice Target$3.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media ContraFect MarketRank™ ForecastAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside3,143.2% Upside$3.00 Price TargetShort InterestHealthy2.40% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.26Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.43) to ($1.23) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.02 out of 5 stars 3.3 Analyst's Opinion Consensus RatingContraFect has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on no buy ratings, 3 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $3.00, ContraFect has a forecasted upside of 3,143.2% from its current price of $0.09.Amount of Analyst CoverageContraFect has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted2.40% of the outstanding shares of ContraFect have been sold short.Short Interest Ratio / Days to CoverContraFect has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in ContraFect has recently increased by 153.44%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldContraFect does not currently pay a dividend.Dividend GrowthContraFect does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CFRX. Previous Next 2.9 News and Social Media Coverage News SentimentContraFect has a news sentiment score of 0.26. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.75 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for ContraFect this week, compared to 1 article on an average week.Search Interest2 people have searched for CFRX on MarketBeat in the last 30 days. MarketBeat Follows3 people have added ContraFect to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ContraFect insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.24% of the stock of ContraFect is held by insiders.Percentage Held by InstitutionsOnly 27.34% of the stock of ContraFect is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for ContraFect are expected to grow in the coming year, from ($1.43) to ($1.23) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ContraFect is -0.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ContraFect is -0.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioContraFect has a P/B Ratio of 0.07. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About ContraFect (NASDAQ:CFRX) StockContraFect Corp. is a clinical stage biotechnology company, which engages in discovering and developing direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. Its product pipeline consists of CF-301, Gram-Negative Lysins and Amurin Peptides. The company was founded by Robert Nowinski on March 5, 2008 and is headquartered in Yonkers, NY.Read More Receive CFRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ContraFect and its competitors with MarketBeat's FREE daily newsletter. Email Address CFRX Stock News HeadlinesJanuary 25, 2023 | americanbankingnews.comContraFect (NASDAQ:CFRX) Coverage Initiated at StockNews.comJanuary 17, 2023 | americanbankingnews.comContraFect (NASDAQ:CFRX) Earns Sell Rating from Analysts at StockNews.comJanuary 26, 2023 | Investing Trends (Ad)Apple, Amazon, and Walmart are Investing in Solar EnergyThe global market for solar energy is expected to be worth an astronomical $1 trillion by the end of 2028, with increasing adoption of solar by commercial, non-profit, and public entities. Even Fortune 500 companies such as Apple, Amazon, and Walmart are investing in solar to help save money over the long term. So it's little wonder solar is also becoming one of the fastest growing sectors in the U.S. stock market.December 20, 2022 | finance.yahoo.comContraFect Announces Lopsided Interim Results From Pivotal Bacterial Infection StudyDecember 19, 2022 | finance.yahoo.comContraFect Provides Update from the Futility Analysis of the Phase 3 DISRUPT Study of ExebacaseDecember 13, 2022 | finance.yahoo.comContraFect Announces Pricing of $7.0 Million Registered Direct Offering and Concurrent Private PlacementNovember 30, 2022 | finance.yahoo.comCFRX: Cleared to Begin Clinical Trial for Exebacase in Chronic Prosthetic Joint Infection…November 28, 2022 | finance.yahoo.comContraFect Announces ANSM Approval of Clinical Trial Application for Exebacase in Prosthetic Joint InfectionsJanuary 26, 2023 | Investing Trends (Ad)Apple, Amazon, and Walmart are Investing in Solar EnergyThe global market for solar energy is expected to be worth an astronomical $1 trillion by the end of 2028, with increasing adoption of solar by commercial, non-profit, and public entities. Even Fortune 500 companies such as Apple, Amazon, and Walmart are investing in solar to help save money over the long term. So it's little wonder solar is also becoming one of the fastest growing sectors in the U.S. stock market.November 22, 2022 | finance.yahoo.comCFRX: Exebacase to be Evaluated as Treatment for Prosthetic Joint Infections…November 14, 2022 | finance.yahoo.comContraFect Reports Third Quarter 2022 Financial Results and Provides Corporate UpdateOctober 19, 2022 | benzinga.com12 Health Care Stocks Moving In Wednesday's Pre-Market Session - ContraFect (NASDAQ:CFRX), Acorda Therape - BenzingaSeptember 14, 2022 | uk.investing.comWhy Kaspien Holdings Is Trading Lower By 13%; Here Are 21 Stocks Moving Premarket By Benzinga - Investing.com UKSeptember 12, 2022 | finance.yahoo.comContraFect Announces Multiple Publications Highlighting the Potential Utility of Lysins for the Treatment of Bone and Joint Infections - Yahoo FinanceSeptember 12, 2022 | baystreet.caContraFect Retreats on PublicationSeptember 12, 2022 | globenewswire.comContraFect Announces Multiple Publications Highlighting the Potential Utility of Lysins for the Treatment of Bone and Joint Infections - GlobeNewswireSeptember 12, 2022 | finance.yahoo.comContraFect Announces Presentation of New Clinical Data From a Study Using Exebacase in the LysinDAIR Procedure on Patients With Chronic Knee Prosthetic Joint InfectionSeptember 12, 2022 | finance.yahoo.comContraFect Announces Multiple Publications Highlighting the Potential Utility of Lysins for the Treatment of Bone and Joint InfectionsSeptember 9, 2022 | streetinsider.comForm SC 13G/A CONTRAFECT Corp Filed by: FEDERATED HERMES, INC. - StreetInsider.comSeptember 7, 2022 | benzinga.comContraFect (CFRX) – CFRX: Exebacase Shows Potent Antimicrobial Activity in Implant-Associated MRSA Osteomyelitis… - BenzingaSeptember 6, 2022 | reuters.comCFRX.A - ContraFect Corp | Stock Price & Latest News | ReutersSeptember 1, 2022 | finance.yahoo.comCFRX: Exebacase Shows Potent Antimicrobial Activity in Implant-Associated MRSA Osteomyelitis…August 23, 2022 | finance.yahoo.comContraFect Cuts Workforce After Trial SetbackAugust 17, 2022 | finance.yahoo.comContraFect Reports Second Quarter 2022 Financial Results and Provides Corporate Update - Yahoo FinanceAugust 16, 2022 | morningstar.comTech startup layoffs approach 71000 in 2022 - MorningstarAugust 16, 2022 | benzinga.comContraFect: Q2 Earnings Insights - BenzingaAugust 16, 2022 | marketwatch.comTech startup layoffs approach 71,000 in 2022 - MarketWatchSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive CFRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ContraFect and its competitors with MarketBeat's FREE daily newsletter. Email Address CFRX Company Calendar Last Earnings11/14/2022Today1/26/2023Next Earnings (Estimated)3/23/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CFRX CUSIPN/A CIK1478069 Webwww.contrafect.com Phone(914) 207-2300FaxN/AEmployees38Year FoundedN/APrice Target and Rating Average Stock Price Forecast$3.00 High Stock Price Forecast$7.00 Low Stock Price Forecast$1.00 Forecasted Upside/Downside+3,175.1%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.51) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-20,280,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-267.63% Return on Assets-127.85% Debt Debt-to-Equity RatioN/A Current Ratio0.84 Quick Ratio0.84 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.26 per share Price / Book0.07Miscellaneous Outstanding Shares43,683,000Free Float41,831,000Market Cap$4.00 million OptionableNot Optionable Beta0.50 Key ExecutivesRoger J. PomerantzChairman, President & Chief Executive OfficerMichael MessingerChief Financial OfficerRaymond SchuchVice President-ResearchGary WoodnuttSenior Vice President-Translational ServicesMatthew SalamoneVice President-Human ResourcesKey CompetitorsAdvaxisNASDAQ:ADXSKiora PharmaceuticalsNASDAQ:KPRXFirst Wave BioPharmaNASDAQ:FWBIHistogenNASDAQ:HSTOAmpio PharmaceuticalsNYSE:AMPEView All CompetitorsInsiders & InstitutionsFNY Investment Advisers LLCSold 15 shares on 1/10/2023Ownership: 0.000%Vanguard Group Inc.Sold 936,118 shares on 11/15/2022Ownership: 1.600%BVF Inc. ILSold 3,500,000 shares on 11/15/2022Ownership: 1.201%Two Sigma Investments LPBought 232,651 shares on 11/15/2022Ownership: 0.591%Boothbay Fund Management LLCSold 26,800 shares on 11/14/2022Ownership: 0.000%View All Institutional Transactions CFRX Stock - Frequently Asked Questions Should I buy or sell ContraFect stock right now? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ContraFect in the last year. There are currently 3 hold ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" CFRX shares. View CFRX analyst ratings or view top-rated stocks. What is ContraFect's stock price forecast for 2023? 4 analysts have issued 12 month price targets for ContraFect's shares. Their CFRX share price forecasts range from $1.00 to $7.00. On average, they expect the company's share price to reach $3.00 in the next year. This suggests a possible upside of 3,057.9% from the stock's current price. View analysts price targets for CFRX or view top-rated stocks among Wall Street analysts. How have CFRX shares performed in 2023? ContraFect's stock was trading at $0.0960 at the beginning of the year. Since then, CFRX stock has decreased by 1.0% and is now trading at $0.0950. View the best growth stocks for 2023 here. Are investors shorting ContraFect? ContraFect saw a increase in short interest during the month of January. As of January 15th, there was short interest totaling 1,050,000 shares, an increase of 153.4% from the December 31st total of 414,300 shares. Based on an average daily volume of 6,130,000 shares, the days-to-cover ratio is currently 0.2 days. View ContraFect's Short Interest. When is ContraFect's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 23rd 2023. View our CFRX earnings forecast. How were ContraFect's earnings last quarter? ContraFect Co. (NASDAQ:CFRX) released its quarterly earnings results on Monday, November, 14th. The biotechnology company reported ($0.43) earnings per share for the quarter, missing analysts' consensus estimates of ($0.23) by $0.20. When did ContraFect's stock split? Shares of ContraFect reverse split on Tuesday, February 4th 2020. The 1-10 reverse split was announced on Tuesday, February 4th 2020. The number of shares owned by shareholders was adjusted after the market closes on Monday, February 3rd 2020. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What other stocks do shareholders of ContraFect own? Based on aggregate information from My MarketBeat watchlists, some companies that other ContraFect investors own include SCYNEXIS (SCYX), Inovio Pharmaceuticals (INO), Verastem (VSTM), Vaxart (VXRT), Matinas BioPharma (MTNB), VBI Vaccines (VBIV), Novavax (NVAX), Cidara Therapeutics (CDTX), Gilead Sciences (GILD) and Dynavax Technologies (DVAX). What is ContraFect's stock symbol? ContraFect trades on the NASDAQ under the ticker symbol "CFRX." Who are ContraFect's major shareholders? ContraFect's stock is owned by a number of institutional and retail investors. Top institutional investors include FNY Investment Advisers LLC (0.00%). View institutional ownership trends. How do I buy shares of ContraFect? Shares of CFRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is ContraFect's stock price today? One share of CFRX stock can currently be purchased for approximately $0.10. How much money does ContraFect make? ContraFect (NASDAQ:CFRX) has a market capitalization of $4.15 million. The biotechnology company earns $-20,280,000.00 in net income (profit) each year or ($1.51) on an earnings per share basis. How can I contact ContraFect? ContraFect's mailing address is 28 WELLS AVENUE 3RD FLOOR, YONKERS NY, 10701. The official website for the company is www.contrafect.com. The biotechnology company can be reached via phone at (914) 207-2300 or via email at mmessinger@contrafect.com. This page (NASDAQ:CFRX) was last updated on 1/26/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.